Focused On-demand Library for Baculoviral IAP repeat-containing protein 7

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.







Alternative names:

Kidney inhibitor of apoptosis protein; Livin; Melanoma inhibitor of apoptosis protein; RING finger protein 50; RING-type E3 ubiquitin transferase BIRC7

Alternative UPACC:

Q96CA5; Q9BQV0; Q9H2A8; Q9HAP7


Baculoviral IAP repeat-containing protein 7 (BIRC7), also known as Livin, plays a pivotal role in apoptosis regulation, cell proliferation, and cell cycle control. It exhibits both proapoptotic and anti-apoptotic activities, mediated through the inhibition of caspases and its E3 ubiquitin-protein ligase activity. BIRC7's ability to ubiquitinate DIABLO/SMAC, targeting it for degradation, underscores its significance in promoting cell survival.

Therapeutic significance:

Understanding the role of Baculoviral IAP repeat-containing protein 7 could open doors to potential therapeutic strategies. Its involvement in apoptosis and cell cycle control makes it a promising target for cancer therapy, offering avenues for the development of novel treatments that manipulate cell death pathways.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.